QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
QuidelOrtho Corp
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 7, 2026
$12.76−0.15 (-1.16%)
Close on Oct 19, 2026
- Market cap
- $871.51M
- P/E (TTM)
- –
- Dividend yield
- –
QuidelOrtho Corp income statement
Ratios
Latest available, balances at Jun 28, 2026
Profitability, TTM
- Gross margin
- 44.6%
- Operating margin
- -30.8%
- Net margin
- -39.2%
- Return on equity, FY2025
- -46.1%
Financial strength
- Current ratio
- 1.39
- Debt to equity
- 1.63
- Debt to assets
- 50.6%
- Cash to current liabilities
- 12.4%
Valuation
- P/E ratio
- –
- Price to sales
- 0.33
- Price to book
- 0.49
- Dividend yield
- –